Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Mzt Holdings

1987 FOUNDED
M&A STATUS
71-80 EMPLOYEES
M&A LATEST DEAL TYPE
$36M LATEST DEAL AMOUNT
Description

Manufacturer & developer of cancer diagnostic technologies and products. The company is a biotechnology company, which engages in the development, manufacture, marketing, distribution, and licensing of cancer diagnostic technologies and products. Its products include NMP22 Test Kit and NMP22 BladderChek Test, which are designed to detect the presence of a specific protein marker in urine correlated with the presence of bladder cancer. Its research and development programs include NMP179 program, a nuclear matrix protein associated with cervical cancer and cervical precancerous conditions; NMP66 program to develop a blood-based test for breast cancer; NMP48 program for prostate cancer; and NMP35, a colon cancer program. In addition, it sells allergy and other diagnostic products manufactured by others. The company sells its products directly to physicians, hospitals, clinics, and physician office laboratories in the United States and Germany, as well as to distributors in other parts of Europe.

Formerly Known As
Matritech
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Primary Office
  • 330 Nevada St
  • Newton, MA 02460
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Mzt Holdings’s full profile, request a free trial.

Mzt Holdings Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Merger/Acquisition 01-Aug-2007 $36M 0000 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »